Malignant Lymphoma Clinical Trial
Official title:
Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma
The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.
The trial of the dose escalation method is from 18mg/m2 until the maximum tolerated dose and every 3 patient is a dose group. ;
Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03346096 -
TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma
|
Phase 2 | |
| Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
| Completed |
NCT01473095 -
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
|
Phase 1 | |
| Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
| Completed |
NCT00685997 -
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
|
N/A | |
| Not yet recruiting |
NCT06358001 -
EchoTip AcuCore Post-Market Clinical Study
|
||
| Recruiting |
NCT04986293 -
CPAP or BiPAP for Motion Mitigation During Radiotherapy
|
N/A | |
| Completed |
NCT01588548 -
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT04464889 -
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Completed |
NCT03316144 -
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
|
Phase 1 | |
| Terminated |
NCT01016795 -
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
|
Phase 2 | |
| Completed |
NCT04464590 -
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
|
||
| Recruiting |
NCT04698616 -
Lean Body Mass and Side Effects in Patients With Lymphoma
|
||
| Active, not recruiting |
NCT02678299 -
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
|
Phase 1/Phase 2 | |
| Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT01789060 -
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
|
N/A | |
| Completed |
NCT05827341 -
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
|
||
| Active, not recruiting |
NCT05515029 -
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
|
Phase 3 | |
| Not yet recruiting |
NCT05545202 -
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
|
Phase 4 |